H. Lundbeck A/S- Stock Price, News & Analysis (OTCMKTS:HLUYY)

$51.92 1.11 (2.18 %)
(As of 01/19/2018 01:53 PM ET)
Previous Close$51.82
Today's Range$51.77 - $51.99
52-Week Range$40.70 - $66.67
Volume942 shs
Average Volume3,786 shs
Market Capitalization$10.45 billion
P/E Ratio26.90
Dividend Yield0.45%
Beta0.17

About H. Lundbeck A/S- (OTCMKTS:HLUYY)

H. Lundbeck A/S- logoH Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Receive HLUYY News and Ratings via Email

Sign-up to receive the latest news and ratings for HLUYY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:HLUYY
CUSIPN/A
Phone45-3630-1311

Debt

Debt-to-Equity Ratio0.07%
Current Ratio1.36%
Quick Ratio1.13%

Price-To-Earnings

Trailing P/E Ratio26.9016419774196
Forward P/E Ratio21.28
P/E Growth0.96

Sales & Book Value

Annual Sales$2.32 billion
Price / Sales4.45
Cash Flow$1.63 per share
Price / Cash31.78
Book Value$7.29 per share
Price / Book7.12

Profitability

Trailing EPS$1.93
Net Income$179.95 million
Net Margins15.07%
Return on Equity30.48%
Return on Assets15.87%

Miscellaneous

EmployeesN/A
Outstanding Shares199,050,000

H. Lundbeck A/S- (OTCMKTS:HLUYY) Frequently Asked Questions

What is H. Lundbeck A/S-'s stock symbol?

H. Lundbeck A/S- trades on the OTCMKTS under the ticker symbol "HLUYY."

How were H. Lundbeck A/S-'s earnings last quarter?

H. Lundbeck A/S- (OTCMKTS:HLUYY) issued its quarterly earnings data on Wednesday, November, 8th. The company reported $0.73 earnings per share (EPS) for the quarter. H. Lundbeck A/S- had a return on equity of 30.48% and a net margin of 15.07%. View H. Lundbeck A/S-'s Earnings History.

When will H. Lundbeck A/S- make its next earnings announcement?

H. Lundbeck A/S- is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for H. Lundbeck A/S-.

Who are some of H. Lundbeck A/S-'s key competitors?

Who are H. Lundbeck A/S-'s key executives?

H. Lundbeck A/S-'s management team includes the folowing people:

  • Lars Rasmussen, Independent Chairman of the Board (Age 58)
  • Anders Goetzsche, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President (Age 49)
  • Lene Skole, Deputy Chairman of the Board (Age 57)
  • Peter E. Anastasiou, Executive Vice President, North America
  • Lars Bang, Executive Vice President, Supply Operations & Engineering (Age 54)
  • Anders Gersel Pedersen M.D., Ph.D., Executive Vice President, Research and Development (Age 65)
  • Jacob Tolstrup, Executive Vice President, Commercial Operations (Age 45)
  • Mona Elisabeth Elster, Director, Employee Representative (Age 54)
  • Lars Holmqvist, Director (Age 57)
  • Jeremy M. Levin, Director (Age 63)

How do I buy H. Lundbeck A/S- stock?

Shares of H. Lundbeck A/S- can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is H. Lundbeck A/S-'s stock price today?

One share of H. Lundbeck A/S- stock can currently be purchased for approximately $51.92.

How big of a company is H. Lundbeck A/S-?

H. Lundbeck A/S- has a market capitalization of $10.45 billion and generates $2.32 billion in revenue each year. The company earns $179.95 million in net income (profit) each year or $1.93 on an earnings per share basis.

How can I contact H. Lundbeck A/S-?

H. Lundbeck A/S-'s mailing address is Ottiliavej 9 Valby, Copenhagen G7, 2500. The company can be reached via phone at 45-3630-1311 or via email at [email protected]


MarketBeat Community Rating for H. Lundbeck A/S- (HLUYY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about H. Lundbeck A/S- and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

H. Lundbeck A/S- (OTCMKTS:HLUYY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.501.501.502.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

H. Lundbeck A/S- (OTCMKTS:HLUYY) Consensus Price Target History

Price Target History for H. Lundbeck A/S- (OTCMKTS:HLUYY)

H. Lundbeck A/S- (OTCMKTS:HLUYY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
7/28/2017Deutsche BankDowngradeHold -> SellView Rating Details
4/12/2017Jefferies GroupDowngradeBuy -> HoldView Rating Details
2/11/2016DNB MarketsUpgradeHold -> BuyView Rating Details
(Data available from 1/19/2016 forward)

Earnings

H. Lundbeck A/S- (OTCMKTS:HLUYY) Earnings History and Estimates Chart

Earnings by Quarter for H. Lundbeck A/S- (OTCMKTS:HLUYY)

H. Lundbeck A/S- (OTCMKTS HLUYY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
11/8/2017Q3 2017$0.73ViewN/AView Earnings Details
8/9/2017Q2 2017$0.60ViewN/AView Earnings Details
5/10/2017Q1 2017$0.51$0.56ViewN/AView Earnings Details
2/8/2017Q4 2016$0.31$0.51ViewN/AView Earnings Details
11/2/2016Q3 2016$0.49ViewN/AView Earnings Details
8/24/2016Q2 2016$0.35ViewN/AView Earnings Details
5/11/2016Q1 2016$0.31ViewN/AView Earnings Details
11/4/2015Q3 2015$0.01$0.17$514.82 million$547.05 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.07$0.10ViewN/AView Earnings Details
2/5/2015Q4 2014($0.24)($0.16)$529.61 million$499.13 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.13ViewN/AView Earnings Details
8/7/2014Q2 2014$0.12$0.13$631.79 million$618.00 millionViewN/AView Earnings Details
5/7/2014Q1 2014$0.39$0.42$690.02 million$668.29 millionViewN/AView Earnings Details
2/6/2014Q4 2013$0.84$0.02ViewN/AView Earnings Details
11/6/2013Q3 2013$0.20$0.25ViewN/AView Earnings Details
8/7/2013Q2 2013$0.20($0.45)ViewN/AView Earnings Details
5/1/2013Q1 2013$0.68$0.81ViewN/AView Earnings Details
2/6/2013Q4 2012$0.68$0.13ViewN/AView Earnings Details
11/7/2012Q3 2012$0.68$0.37ViewN/AView Earnings Details
8/8/2012Q2 2012$0.40($0.07)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.68$0.56ViewN/AView Earnings Details
2/8/2012Q4 2011$0.39$0.18ViewN/AView Earnings Details
11/9/2011Q3 2011$0.68$0.34ViewN/AView Earnings Details
8/10/2011Q2 2011$0.71$0.78ViewN/AView Earnings Details
5/4/2011Q1 2011$0.61$0.87ViewN/AView Earnings Details
11/3/2010Q3 2010$0.60ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

H. Lundbeck A/S- (OTCMKTS:HLUYY) Earnings Estimates

Current Year EPS Consensus Estimate: $2.44 EPS
Next Year EPS Consensus Estimate: $2.61 EPS

Dividends

Dividend History for H. Lundbeck A/S- (OTCMKTS:HLUYY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for H. Lundbeck A/S- (OTCMKTS HLUYY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

H. Lundbeck A/S- (OTCMKTS HLUYY) News Headlines

Source:
DateHeadline
H. Lundbeck A/S- Expected to Post FY2017 Earnings of $2.44 Per Share (HLUYY)H. Lundbeck A/S- Expected to Post FY2017 Earnings of $2.44 Per Share (HLUYY)
www.americanbankingnews.com - January 18 at 6:44 AM
Tevas Trisenox Gets FDA Approval as First-Line TreatmentTeva's Trisenox Gets FDA Approval as First-Line Treatment
www.zacks.com - January 16 at 10:08 AM
Pfizers Leukemia Drug Gets FDA Nod in First-Line SettingPfizer's Leukemia Drug Gets FDA Nod in First-Line Setting
finance.yahoo.com - December 20 at 3:57 PM
Pfizer Hikes Dividend, Announces $10B Share Buyback PlanPfizer Hikes Dividend, Announces $10B Share Buyback Plan
www.zacks.com - December 19 at 10:10 AM
H. Lundbeck A/S- (HLUYY) Upgraded by Zacks Investment Research to BuyH. Lundbeck A/S- (HLUYY) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 16 at 12:06 AM
H. Lundbeck A/S- (HLUYY) Downgraded by Zacks Investment Research to HoldH. Lundbeck A/S- (HLUYY) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - December 14 at 11:26 PM
Sanofi Wins FDA Approval for Biosimilar of Lillys HumalogSanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
finance.yahoo.com - December 12 at 10:36 AM
AbbVie Psoriasis Candidate Succeeds in 4th Phase III StudyAbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
www.nasdaq.com - December 5 at 12:45 PM
H Lundbeck A/S (HLUYY) Lifted to Buy at Zacks Investment ResearchH Lundbeck A/S (HLUYY) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:32 AM
U.S. FDA approves Carnexiv™ (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulationsU.S. FDA approves Carnexiv™ (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
globenewswire.com - October 8 at 5:07 PM
Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s diseaseHeadline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s disease
globenewswire.com - September 22 at 5:29 PM
The General Court of the EU upholds the European Commissions 2013 fining decision against LundbeckThe General Court of the EU upholds the European Commission's 2013 fining decision against Lundbeck
globenewswire.com - September 9 at 10:09 AM
Lundbeck increases its share capital by 97,349 shares (0.0493 % of outstanding shares) as a result of exercise of employee warrantsLundbeck increases its share capital by 97,349 shares (0.0493 % of outstanding shares) as a result of exercise of employee warrants
globenewswire.com - September 7 at 5:37 PM
Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
globenewswire.com - July 7 at 5:33 PM
Brexit Would Put EU Drug Regulator’s Headquarters in PlayBrexit Would Put EU Drug Regulator’s Headquarters in Play
www.wsj.com - June 17 at 8:12 AM
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entitiesTransactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
globenewswire.com - June 2 at 5:43 PM
Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016 - GlobeNewswire (press release)Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016 - GlobeNewswire (press release)
globenewswire.com - March 2 at 2:56 PM
H. Lundbeck A/S increases its share capital by 40104 shares (0.0203 % of outstanding shares) as a result of employee ... - GlobeNewswire (press release)H. Lundbeck A/S increases its share capital by 40104 shares (0.0203 % of outstanding shares) as a result of employee ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 2:31 PM
H LUNDBECK A/SH LUNDBECK A/S
www.finanznachrichten.de - February 23 at 2:31 PM
European Stocks Drop More Than 1% on Weak EarningsEuropean Stocks Drop More Than 1% on Weak Earnings
www.thestreet.com - August 19 at 7:29 AM

SEC Filings

H. Lundbeck A/S- (OTCMKTS:HLUYY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

H. Lundbeck A/S- (OTCMKTS HLUYY) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.